Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes.
Fiche publication
Date publication
novembre 2023
Journal
Cardiovascular diabetology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence, Pr PETIT Jean-Michel, Pr VERGES Bruno, Dr PAIS DE BARROS Jean-Paul
Tous les auteurs :
Denimal D, Béland-Bonenfant S, Pais-de-Barros JP, Rouland A, Bouillet B, Duvillard L, Vergès B, Petit JM
Lien Pubmed
Résumé
There is growing evidence that ceramides play a significant role in the onset and progression of non-alcoholic fatty liver disease (NAFLD), a highly prevalent condition in patients with type 2 diabetes associated with hepatic and cardiovascular events. However, the relationship between plasma ceramide levels and NAFLD severity in type 2 diabetes remains unclear. The main purpose of the present study was to investigate whether circulating levels of ceramides in patients with type 2 diabetes are associated with liver steatosis assessed by the highly accurate magnetic resonance imaging proton density fat fraction (MRI-PDFF). The secondary objective was to assess the relationship between plasma ceramides and noninvasive scores of liver fibrosis.
Mots clés
Ceramides, Liver fibrosis, Liver steatosis, Type 2 diabetes
Référence
Cardiovasc Diabetol. 2023 11 8;22(1):310